Medavie Blue Cross Leads Digital Transformation in Disability Business with FINEOS Platform
ATLANTA--(BUSINESS WIRE)-- FINEOS Corporation (ASX:FCL) announced today that Medavie Blue Cross, a leading benefits provider for health, drug and disability insurance, has successfully commenced managing Individual Life and Disability Claims on their existing FINEOS Platform. In consolidating both Individual Life and Group Life & Disability claims on a single, unified platform, Medavie Blue Cross will further strengthen its operational excellence and customer-centric service.
By consolidating on the FINEOS Platform, Medavie Blue Cross is driving operational excellence, empowering teams, and reimagining the claims experience for clients across Canada.
Share
Speaking about the go-live, FINEOS CEO, Michael Kelly, said, 'Medavie Blue Cross has been leading the way in Group Disability claims management with FINEOS. Expanding to include Individual Life claims in one platform marks a significant milestone, demonstrating our shared commitment to innovation, operational efficiency and a seamless customer experience.'
Rebecca Smith, Director, Life & Disability Services at Medavie Blue Cross, noted, 'We're excited about the possibilities this opens up for our organization and our clients. By unifying our claims management system, we're not just improving efficiency; we're reimagining the entire claims experience and empowering our talented team to deliver exceptional service. This transition reinforces our position as an industry leader in disability management and in embracing digital transformation to set new standards.'
About Medavie Blue Cross
Medavie Blue Cross is a leading all-in-one private health insurer and Canada's largest private administrator of federal and provincial government-sponsored health programs. We manage and insure health benefits for nearly 1 in 10 Canadians and provide timely access to quality health care through a comprehensive suite of innovative products and services. Together with Medavie Health Services, a national leader in primary health care solutions and Canada's largest contracted provider of emergency medical services, we're part of Medavie — a not-for-profit health solutions partner committed to improving the wellbeing of Canadians.
About FINEOS Corporation
FINEOS is a leading global provider of SaaS core systems for life, accident, and health insurers. The FINEOS Platform for Employee Benefits is purpose-built for group, absence, and supplemental benefits, providing seamless integration and automation. More than 40 customers in North America rely on FINEOS, including 7 of the 10 largest employee benefits insurers in the U.S. and 70% of group insurance in Australia. With a global workforce, FINEOS partners with innovative, forward-thinking insurers in North America, EMEA, and Asia-Pacific.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
MA Financial Group Sticks to Its Buy Rating for IPD Group Ltd (IPG)
In a report released on May 30, Matthew Chen CFA from MA Financial Group maintained a Buy rating on IPD Group Ltd (IPG – Research Report), with a price target of A$4.21. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Chen CFA is a 5-star analyst with an average return of 21.9% and a 66.67% success rate. Chen CFA covers the Industrials sector, focusing on stocks such as Acrow Formwork and Construction Services Limited, Southern Cross Electrical Engineering Limited, and NRW Holdings Limited. In addition to MA Financial Group, IPD Group Ltd also received a Buy from Bell Potter's Joseph House in a report issued on May 29. However, on the same day, PAC Partners maintained a Hold rating on IPD Group Ltd (ASX: IPG).
Yahoo
3 hours ago
- Yahoo
VEEM (ASX:VEE) shareholders have earned a 18% CAGR over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. For example, the VEEM Ltd (ASX:VEE) share price has soared 120% in the last half decade. Most would be very happy with that. Unfortunately, though, the stock has dropped 4.9% over a week. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During five years of share price growth, VEEM achieved compound earnings per share (EPS) growth of 9.1% per year. This EPS growth is slower than the share price growth of 17% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. You can see below how EPS has changed over time (discover the exact values by clicking on the image). It might be well worthwhile taking a look at our free report on VEEM's earnings, revenue and cash flow. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, VEEM's TSR for the last 5 years was 130%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. VEEM shareholders are down 51% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 18%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for VEEM that you should be aware of before investing here. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
ASX Penny Stocks To Watch In June 2025
The ASX200 is set to open slightly lower today, influenced by mixed performances in the US markets and ongoing global trade tensions. Despite these broader market challenges, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth. While the term 'penny stock' may seem outdated, these investments can still reveal hidden value when backed by strong financial health and solid fundamentals. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.85 A$149.01M ★★★★☆☆ Accent Group (ASX:AX1) A$1.90 A$1.14B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.565 A$73.83M ★★★★★★ IVE Group (ASX:IGL) A$2.55 A$393.16M ★★★★★☆ GTN (ASX:GTN) A$0.61 A$116.42M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.50 A$166.08M ★★★★★★ Regal Partners (ASX:RPL) A$2.33 A$783.26M ★★★★★★ Tasmea (ASX:TEA) A$2.99 A$699.78M ★★★★★☆ SHAPE Australia (ASX:SHA) A$3.29 A$272.21M ★★★★★★ Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Emerald Resources NL is involved in the exploration and development of mineral reserves in Cambodia and Australia, with a market cap of A$3.12 billion. Operations: The company generates revenue primarily from its mine operations, amounting to A$427.32 million. Market Cap: A$3.12B Emerald Resources demonstrates strong financial health with its interest payments well covered by EBIT and operating cash flow covering debt over tenfold. Its net profit margin has improved, reflecting a stable growth trajectory, while earnings have consistently outpaced the industry average. The company trades significantly below estimated fair value and has not diluted shareholders recently. Despite a low return on equity, Emerald's cash reserves exceed total debt, indicating prudent financial management. The seasoned board and management team further bolster confidence in its operations. However, earnings growth has decelerated compared to the past five years but remains robust overall. Click here and access our complete financial health analysis report to understand the dynamics of Emerald Resources. Explore Emerald Resources' analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Lindsay Australia Limited offers integrated transport, logistics, and rural supply services to the food processing, food services, fresh produce, and horticulture sectors in Australia, with a market cap of A$225.19 million. Operations: The company's revenue is primarily derived from its Transport segment at A$573.35 million, followed by Rural at A$160.92 million and Hunters at A$100.09 million, with an additional contribution from Corporate activities amounting to A$5.15 million. Market Cap: A$225.19M Lindsay Australia presents a mixed picture for investors. While its earnings have grown significantly over the past five years, recent performance shows negative earnings growth and a decline in profit margins. The company's short-term assets exceed its short-term liabilities, but they fall short of covering long-term liabilities. Despite trading below estimated fair value and having well-covered debt by operating cash flow, the stock's return on equity is low and dividend track record unstable. Recent strategic moves include potential acquisition talks with SRT Logistics and a board addition of an experienced non-executive director, which might influence future growth prospects. Jump into the full analysis health report here for a deeper understanding of Lindsay Australia. Gain insights into Lindsay Australia's future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Qualitas (ASX:QAL) is a real estate investment firm specializing in direct investments across various real estate classes and geographies, distressed debt acquisitions and restructuring, third-party capital raisings, and consulting services, with a market cap of A$833.42 million. Operations: Qualitas generates revenue through its Direct Lending segment, which accounts for A$23.03 million, and its Funds Management segment, contributing A$21.46 million. Market Cap: A$833.42M Qualitas demonstrates a robust financial position with significant earnings growth of 21.6% annually over the past five years, supported by strong net profit margins that have improved to 27.6%. The company's short-term assets comfortably cover both short- and long-term liabilities, and it holds more cash than total debt. However, its dividend yield of 2.82% is not well covered by free cash flows, and operating cash flow remains negative. Recent developments include the appointment of Bruce MacDiarmid as an independent non-executive director, potentially enhancing governance given his extensive experience in investment banking and capital markets. Take a closer look at Qualitas' potential here in our financial health report. Understand Qualitas' earnings outlook by examining our growth report. Unlock more gems! Our ASX Penny Stocks screener has unearthed 997 more companies for you to here to unveil our expertly curated list of 1,000 ASX Penny Stocks. Curious About Other Options? Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMR ASX:LAU and ASX:QAL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
